Kristie L. Kahl

Eryaspase, a novel drug candidate, is being evaluated in patients with second-line metastatic pancreatic cancer and those with metastatic triple-negative breast cancer.

The Food and Drug Administration noted the trial design was acceptable for researchers to evaluate VERU-111 in in metastatic castration and novel androgen-blocking agent resistant prostate cancer.

The agent, in combination with the current standard of care, is being evaluated as a frontline treatment for patients with high-risk Denovo Genomic Marker 1 (DGM1)–positive DLBCL.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Ruben Mesa about understanding a myeloproliferative neoplasm diagnosis.

The Food and Drug Administration approved Blenrep to treat patients with relapsed/refractory multiple myeloma.

The Food and Drug Administration approved Monjuvi in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

The V Foundation is set to host its annual Dick Vitale Gala on Sept. 4, 2020, virtually, to help raise funds and awareness for pediatric cancer.

“When time passes, and you look back it seems like a distant memory.”

“You have to speak up. What you don’t say is the most predictive of the care you don’t get.”

Patients can pick from a growing array of treatments, from same-day- results surgery to game-changing immunotherapy, to fight the most common type of cancer.

In this episode of the “CURE Talks Cancer” podcast we spoke with two experts on the treatment landscape of metastatic urothelial carcinoma and what patients have to look forward to.

The Food and Drug Administration approved Bavencio as a first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Jonathon Leventhal about skin cancer and what individuals should know about the disease.

Andrea Dwyer spoke with CURE® about the symposium and why it is important to raise global awareness around the increasing rate of early-age onset colorectal cancer.

The Food and Drug Administration approved the second biomarker-based indication for Keytruda to treat adult and pediatric patients with unresectable or metastatic TMB-H solid tumors across cancer types, including rare cancers.

The phase 3 PROTECTIVE-2 (Study 106) trial met its primary and secondary end points in preventing chemotherapy-induced neutropenia following treatment with plinabulin in combination with Neulasta.

The Food and Drug Administration approved Opdivo for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Drs. Ali Hendi and Jeremy Brauer about skin cancer awareness month.

The Food and Drug Administration approved Alunbrig for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer.

Dr. Brian Rini discussed the benefits of treating patients with relapsed or refractory renal cell carcinoma with the vascular endothelial growth factor tyrosine kinase inhibitor.

The Food and Drug Administration approved the first new treatment option for Kaposi sarcoma in more than 20 years.